Efficacy of treatment with verbascoside, biotechnologically produced by Syringa vulgaris plant cell cultures in an experimental mice model of spinal cord trauma

Naunyn Schmiedebergs Arch Pharmacol. 2010 Oct;382(4):331-45. doi: 10.1007/s00210-010-0537-2. Epub 2010 Aug 27.

Abstract

In this study we evaluated the effect of glycosylated phenylpropanoid verbascoside (VB), isolated from cultured cells of the medicinal plant Syringa vulgaris (Oleaceae) in experimental animal model of spinal cord injury (SCI). SCI was induced by the application of vascular clips to the dura via a four-level T5-T8 laminectomy. SCI in mice resulted in severe trauma characterized by edema, tissue damage, and apoptosis. At 1 and 6 h after injury, the mice were treated with VB extract, administered at the dose of 2 mg/kg with intraperitoneal administration. Immunohistochemical examination demonstrated a marked increase on expression for nitrotyrosine, inducible nitric oxide synthase, poly(ADP-ribose), and apoptosis events (increase of Bax and Bcl-2 expression) in the spinal cord tissue. Additionally, we demonstrate that these inflammatory events were associated with the cytokines expression (TNF-α and IL-1β), neutrophil infiltration (myeloperoxidase), and activation of NF-κB. In contrast, all of these parameters of inflammation were attenuated by treatment with VB. In a separate set of experiment, we have clearly demonstrated that VB treatment significantly ameliorated the recovery of function (evaluated by motor recovery score). Taken together, our results clearly demonstrate that treatment with VB extract reduces the development of inflammation and tissue injury events associated with spinal cord trauma.

MeSH terms

  • Animals
  • Anti-Inflammatory Agents, Non-Steroidal / administration & dosage
  • Anti-Inflammatory Agents, Non-Steroidal / isolation & purification
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
  • Apoptosis / drug effects
  • Blotting, Western
  • Cell Culture Techniques
  • Chromatography, High Pressure Liquid
  • Disease Models, Animal
  • Glucosides / administration & dosage
  • Glucosides / isolation & purification
  • Glucosides / therapeutic use*
  • Immunohistochemistry
  • In Situ Nick-End Labeling
  • Injections, Intraperitoneal
  • Interleukin-1beta / metabolism
  • Male
  • Mice
  • Mice, Inbred Strains
  • Motor Activity / drug effects
  • Nitric Oxide Synthase Type II / biosynthesis
  • Phenols / administration & dosage
  • Phenols / isolation & purification
  • Phenols / therapeutic use*
  • Plant Extracts / administration & dosage
  • Plant Extracts / isolation & purification
  • Plant Extracts / therapeutic use
  • Poly Adenosine Diphosphate Ribose / biosynthesis
  • Proto-Oncogene Proteins / biosynthesis
  • Proto-Oncogene Proteins c-bcl-2
  • Spinal Cord / drug effects*
  • Spinal Cord / immunology
  • Spinal Cord / metabolism
  • Spinal Cord / pathology
  • Spinal Cord Injuries / drug therapy*
  • Spinal Cord Injuries / immunology
  • Spinal Cord Injuries / metabolism
  • Spinal Cord Injuries / pathology
  • Syringa / chemistry*
  • Syringa / cytology
  • Tumor Necrosis Factor-alpha / metabolism
  • Tyrosine / analogs & derivatives
  • Tyrosine / biosynthesis
  • bcl-2-Associated X Protein / biosynthesis

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Bax protein, mouse
  • Glucosides
  • Interleukin-1beta
  • Phenols
  • Plant Extracts
  • Proto-Oncogene Proteins
  • Proto-Oncogene Proteins c-bcl-2
  • Tumor Necrosis Factor-alpha
  • bcl-2-Associated X Protein
  • Bcl2 protein, mouse
  • Poly Adenosine Diphosphate Ribose
  • 3-nitrotyrosine
  • acteoside
  • Tyrosine
  • Nitric Oxide Synthase Type II